Clover Health Investments, Corp. — Form 8-K Summary
Business context and reporting period
This Form 8-K, dated August 5, 2022, and signed August 10, 2022, reports executive succession and related compensation arrangements. The company announced the plan on August 8, 2022. No quarterly financial results or operating-period metrics are provided.
Executive succession and compensation
- Effective January 1, 2023, Co-Founder and CEO Vivek Garipalli will become Executive Chairman of the Board and leave the CEO role.
- Andrew Toy, then President and a director, will become Co-Founder and CEO and will no longer serve as President.
- Beginning January 1, 2023, Mr. Toy will receive a $700,000 annual base salary and a target annual cash incentive equal to 100% of base salary.
- Mr. Toy will receive an $18.0 million restricted stock unit promotion grant: $7.0 million granted August 8, 2022, and $11.0 million scheduled for January 1, 2023.
- Each grant installment vests 25% on its first anniversary, with the remainder vesting in 12 equal quarterly installments, subject to continued service.
- Mr. Toy must retain shares issued upon settlement of the promotion RSUs, excluding shares withheld for taxes, until he holds company stock worth three times his base salary.
Financial metrics and material changes
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating metrics. The material change disclosed is the planned CEO transition and associated executive compensation.
Severance, risks, and contingencies
- If Mr. Toy is terminated without Cause or resigns for Good Reason, he is generally entitled to severance equal to 1.5 times base salary plus target bonus, payment of certain previously earned unpaid bonuses, and 18 months of health benefit continuation.
- If such termination occurs within the three months before or 18 months after a change in control, severance increases to 2.0 times base salary plus target bonus, with 24 months of health benefit continuation.
- Severance is conditioned on execution and non-revocation of a general release of claims.
- The agreement includes confidentiality, 18-month post-employment non-competition and non-solicitation, and mutual non-disparagement obligations.
- The $18.0 million promotion award and potential severance represent compensation obligations subject to vesting, employment status, and applicable agreement terms.
- The complete employment agreement was expected to be filed as an exhibit to the company’s Form 10-Q for the quarter ending September 30, 2022.
Important facts for investors to verify
- Confirm the effective date and completion of the Garipalli-to-Toy CEO transition.
- Review the full 2022 Toy employment agreement and the final terms of both RSU installments.
- Assess the accounting and dilution impact of the $18.0 million promotion grant.
- Review future filings for changes in executive compensation, severance exposure, and equity awards.
- Note that this filing contains no financial results or updated business outlook.